Neurocrine Biosciences has laid off its entire 200-person sales force, the San Diego firm said. The decision follows Pfizer’s ending of its marketing partnership with Neurocrine after the latter lost approval for insomnia drug Indiplon, and Pfizer lost US patent protection for Zoloft.
Neurocrine was then unable to acquire a product to keep the reps busy as it continues to seek FDA approval for Indiplon.
Neurocrine plans to meet with the FDA to finalize plans for the resubmission of each Indiplon NDA and to commercialize Indiplon quickly upon approval.
Neurocrine also said it is reviewing other possible future partnerships.
From the September 01, 2006 Issue of MM+M - Medical Marketing and Media
